ArticlePloS one2025
The effect of angiotensin receptor blockers on peripheral artery disease progression: A retrospective cohort study in Jordan.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral artery disease (PAD) is a common atherosclerotic vascular condition associated with many complications. The specific effect of angiotensin receptor blockers (ARBs) on the short-term complications in PAD patients has not been explored before.
objectivesThis study aimed to evaluate the association between ARBs use and the disease severity, progression, the frequency of surgical interventions, and arterial occlusion rates among users.
methodsA retrospective cohort study was conducted at King Abdullah Ⅱ Hospital, including 133 patients followed between 2019 and 2024. The cohort was divided into two groups based on their exposure to ARBs: the ARBs group and the control group. Data related to patient demographics, clinical characteristics, medical history, laboratory results, vital signs, in addition to clinical outcomes were extracted from electronic medical records. Statistical analysis was performed using SPSS version 27.0.
resultsAmong the participants, 24.8% experienced amputation, with 21.1% in the control group compared to 3.8% in the ARBs group. ARBs group has 79.2% lower Limb amputation (P-value 0.011; OR= 0.208, 95% CI 0.062-0.700) and 71% lower likelihood of having advanced PAD stage (stages III and IV) (P-value = 0.034, OR= 0.294, 95% CI = 0.095-0.911) compared to the control group. Linear regression analysis showed that the ARBs group has a decreased frequency of revascularization procedures (P-value 0.025;95% CI -1.004 - - 0.068).
conclusionARBs may serve as a promising protective treatment option for PAD patients, potentially benefiting disease progression by lowering the risk of amputation and reducing the need for revascularization procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.